Abstract
SEVERAL inflammatory diseases, including asthma, arthritis and psoriasis are associated with the production of leukotrienes by neutrophils, mast cells and macrophages1–3. The initial enzymatic step in the formation of leukotrienes is the oxidation of arachidonic acid by 5-lipoxygenase (5-LO) to leukotriene A4 (refs 4–6). Osteosarcoma cells transfected with 5-LO express active enzyme in broken cell preparations, but no leukotriene metabolites are produced by these cells when stimulated with the calcium ionophore A23187, indicating that an additional component is necessary for cellular 5-LO activity7. A new class of indole leukotriene inhibitor has been described that inhibits the formation of cellular leukotrienes but has no direct inhibitory effect on soluble 5-LO activity8. We have now used these potent agents to identify and isolate a novel membrane protein of relative molecular mass 18,000 which is necessary for cellular leukotriene synthesis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase
Scientific Reports Open Access 24 August 2017
-
FLAP pharmacological blockade modulates metabolism of endogenous tau in vivo
Translational Psychiatry Open Access 03 December 2013
-
Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer’s disease mouse model
Journal of Neuroinflammation Open Access 14 June 2012
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Samuelsson, B. Science 220, 568–575 (1983).
Samuelsson, B., Dahlen, S. E., Lindgren, J. A., Rouzer, C. A. & Serhan, C. N. Science 237, 1171–1176 (1987).
Rokach, J. Leukotrienes and Lipoxygenases (Elsevier, Amsterdam, 1989).
Shimizu, T., Radmark, O. & Samuelsson, B. Proc. natn. Acad. Sci. U.S.A. 81, 689–693 (1984).
Shimizu, T. et al. Proc. natn. Acad. Sci. U.S.A. 83, 4175–4179 (1986).
Rouzer, C. A., Matsumoto, T. & Samuelsson, B. Proc. natn. Acad. Sci. U.S.A. 83, 857–861 (1986).
Rouzer, C. A. et al. J. biol. Chem. 263, 10135–10140 (1988).
Gillard, J. et al. Can. J. Physiol. Pharmac. 67, 456–464 (1989).
Rouzer, C. A. J. biol. Chem. (in the press).
Rouzer, C. A. & Kargman, S. J. biol. Chem. 263, 10980–10988 (1988).
Kuehl, F. A. Jr., Dougherty, H. W. & Ham, E. A. Biochem. Pharmac. 33, 1–5 (1984).
Chilton, F. H. Biochem. J. 258, 327–333 (1989).
Ham, E. A. et al. Proc. natn. Acad. Sci. U.S.A. 80, 4349–4353 (1983).
Boyum, A. Scand. J. clin. Lab. Invest. (suppl. 97) 21, 77–89 (1968).
Guindon, Y. et al. in Advances in Prostaglandin, Thromboxane and Leukotriene Research (eds Samuelsson, B., Paoletti, R. & Ramwell, P. W.) 554–557 (Raven, New York, 1987).
Gan, Z. R. Gene 79, 159–166 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miller, D., Gillard, J., Vickers, P. et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 343, 278–281 (1990). https://doi.org/10.1038/343278a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/343278a0
This article is cited by
-
Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase
Scientific Reports (2017)
-
FLAP pharmacological blockade modulates metabolism of endogenous tau in vivo
Translational Psychiatry (2013)
-
Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer’s disease mouse model
Journal of Neuroinflammation (2012)
-
Lipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention
Current Colorectal Cancer Reports (2012)
-
Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease
Human Genetics (2008)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.